Template:Metoprolol: Difference between revisions
Jump to navigation
Jump to search
Gerald Chi (talk | contribs) mNo edit summary |
Gerald Chi (talk | contribs) mNo edit summary |
||
| Line 7: | Line 7: | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Lopressor dosage and administration|Dosage and Administration]] | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Lopressor dosage and administration|Dosage and Administration]] | ||
|- | |||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Lopressor dosage forms and strengths|Dosage Forms and Strengths]] | |||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Lopressor contraindications|Contraindications]] | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Lopressor contraindications|Contraindications]] | ||
| Line 23: | Line 25: | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Lopressor clinical pharmacology|Clinical Pharmacology]] | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Lopressor clinical pharmacology|Clinical Pharmacology]] | ||
|- | |||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Lopressor nonclinical toxicology|Nonclinical Toxicology]] | |||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Lopressor clinical studies|Clinical Studies]] | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Lopressor clinical studies|Clinical Studies]] | ||
| Line 37: | Line 41: | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Toprol XL dosage and administration|Dosage and Administration]] | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Toprol XL dosage and administration|Dosage and Administration]] | ||
|- | |||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Toprol XL dosage forms and strengths|Dosage Forms and Strengths]] | |||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Toprol XL contraindications|Contraindications]] | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Toprol XL contraindications|Contraindications]] | ||
| Line 53: | Line 59: | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Toprol XL clinical pharmacology|Clinical Pharmacology]] | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Toprol XL clinical pharmacology|Clinical Pharmacology]] | ||
|- | |||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Toprol XL nonclinical toxicology|Nonclinical Toxicology]] | |||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Toprol XL clinical studies|Clinical Studies]] | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Toprol XL clinical studies|Clinical Studies]] | ||
| Line 62: | Line 70: | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Toprol XL labels and packages|Labels and Packages]] | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Toprol XL labels and packages|Labels and Packages]] | ||
|- | |- | ||
! style="padding: 0 5px; font-size: 85%; background:#F5F5F5 | ! style="padding: 0 5px; font-size: 85%; background:#F5F5F5" align=left | [http://clinicaltrials.gov/search/open/condition={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}} Clinical Trials on Metoprolol] | ||
|- | |- | ||
|} | |} | ||